文献速递肝病消化道肿瘤与早癌

CRAFITY评分预测肝细胞癌免疫治疗预后

Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.
PubMed 文献 · J Hepatol · 2021-10-12

该研究基于190例训练集和102例验证集构建并外部验证了CRAFITY评分,用于预测接受PD-(L)1免疫治疗的肝细胞癌患者生存和影像学反应。基线AFP≥100 ng/ml和CRP≥1 mg/dl为独立预后因素,评分0、1、2分中位OS分别为27.6、11.3、6.4个月。

要点

  • 基线AFP≥100 ng/ml和CRP≥1 mg/dl为独立预后因素
  • CRAFITY评分0、1、2分中位OS分别为27.6、11.3、6.4个月
  • 低评分患者影像学最佳反应显著更优,p=0.003

核心结论

  • CRAFITY评分与接受PD-(L)1免疫治疗肝细胞癌患者的总生存和影像学反应相关。

研究设计与样本

  • 训练集190例来自6个欧洲中心,验证集102例来自8个欧洲中心,另在204例索拉非尼治疗队列中评估。
  • 采用Cox模型分析基线变量对总生存的预后价值并构建CRAFITY评分。

主要发现

  • 基线AFP≥100 ng/ml风险比1.7,p=0.007;基线CRP≥1 mg/dl风险比1.7,p=0.007。
  • CRAFITY-low(0分)中位OS 27.6个月(95%CI 19.5-35.8)。
  • CRAFITY-intermediate(1分)中位OS 11.3个月(95%CI 8.0-14.6)。
  • CRAFITY-high(2分)中位OS 6.4个月(95%CI 4.8-8.1),组间p<0.001。
  • 最佳影像学反应在低评分组更优(CRAFITY-low完全缓解9%、部分缓解20%、疾病稳定52%、疾病进展20%;CRAFITY-intermediate分别为3%、25%、36%、36%;CRAFITY-high分别为2%、15%、22%、61%;p=0.003)。

关键数值与推荐

  • CRAFITY评分基于基线AFP≥100 ng/ml和CRP≥1 mg/dl两项指标,各计1分。

临床怎么用

  • 该评分可能有助于患者咨询,但需前瞻性验证。

局限性

  • 需要前瞻性验证。
  • 在索拉非尼队列中CRAFITY与生存相关,但与影像学反应无关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Immunotherapy with atezolizumab plus bevacizumab represents the new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC). However, biomarkers that predict treatment success and survival remain an unmet need. METHODS: Patients with HCC put on PD-(L)1-based immunotherapy were included in a training set (n = 190; 6 European centers) and a validation set (n = 102; 8 European centers). We investigated the prognostic value of baseline variables on overall survival using a Cox model in the training set and developed the easily applicable CRAFITY (CRP and AFP in ImmunoTherapY) score. The score was validated in the independent, external cohort, and evaluated in a cohort of patients treated with sorafenib (n = 204). RESULTS: Baseline serum alpha-fetoprotein ≥100 ng/ml (hazard ratio [HR] 1.7; p = 0.007) and C-reactive protein ≥1 mg/dl (HR, 1.7; p = 0.007) were identified as independent prognostic factors in multivariable analysis and were used to develop the CRAFITY score. Patients who fulfilled no criterion (0 points; CRAFITY-low) had the longest median overall survival (27.6 (95% CI 19.5-35.8) months), followed by those fulfilling 1 criterion (1 point; CRAFITY-intermediate; 11.3 (95% CI 8.0-14.6) months), and patients meeting both criteria (2 points; CRAFITY-high; 6.4 (95% CI 4.8-8.1) months; p <0.001). Additionally, best radiological response (complete response/partial response/stable disease/progressive disease) was significantly better in patients with lower CRAFITY score (CRAFITY-low: 9%/20%/52%/20% vs. CRAFITY-intermediate: 3%/25%/36%/36% vs. CRAFITY-high: 2%/15%/22%/61%; p = 0.003). These results were confirmed in the independent validation set and in different subgroups, including Child-Pugh A and B, performance status 0 and ≥1, and first-line and later lines. In the sorafenib cohort, CRAFITY was associated with survival, but not radiological response. CONCLUSIONS: The CRAFITY score is associated with survival and radiological response in patients receiving PD-(L)1 immunotherapy. The score may help with patient counseling but requires prospective validation. LAY SUMMARY: The immunotherapy-based regimen of atezolizumab plus bevacizumab represents the new standard of care in systemic first-line therapy of hepatocellular carcinoma (HCC). Biomarkers to predict treatment outcome are an unmet need in patients undergoing immunotherapy for HCC. We developed and externally validated a score that predicts outcome in patients with HCC undergoing immunotherapy with immune checkpoint blockers.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Scheiner B, Pomej K, Kirstein MM, et al. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J Hepatol. 2021. PMID: 34648895. doi:10.1016/j.jhep.2021.09.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。